Business Context and Reporting Period
This Form 8-K was filed by Tocagen Inc. on May 25, 2017. The report details compensatory arrangements approved by the Compensation Committee and Board of Directors for executive officers, effective June 5, 2017. Note: The request metadata referenced "Forte Biosciences, Inc.", but the filing text explicitly identifies the registrant as Tocagen Inc.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
Executive Base Salary Increases
| Name | Title | New Base Salary |
|---|---|---|
| Martin J. Duvall | Chief Executive Officer | $480,000 |
| Harry E. Gruber, M.D. | President, Research and Development | $365,000 |
| Asha Das, M.D. | Senior Vice President and Chief Medical Officer | $370,000 |
| Mark Foletta | Executive Vice President and Chief Financial Officer | $365,000 |
2017 Bonus Plan Targets
Target bonuses are expressed as a percentage of 2017 base salary, weighted by corporate and individual goals.
| Name | Target Bonus % | Corporate Goal Weight | Individual Goal Weight |
|---|---|---|---|
| Martin J. Duvall | 50% | 100% | 0% |
| Harry E. Gruber, M.D. | 40% | 100% | 0% |
| Asha Das, M.D. | 35% | 75% | 25% |
| Mark Foletta | 40% | 100% | 0% |
Stock Option Grants
Options were granted under the 2017 Equity Incentive Plan with an exercise price of $16.32 per share (closing price on May 26, 2017). Vesting is over four years (25% after one year, monthly thereafter).
| Name | Shares Underlying Options | |
|---|---|---|
| Martin J. Duvall | 285,000 | |
| Harry E. Gruber, M.D. | 40,000 | |
| Asha Das, M.D. | 130,000 | |
| Mark Foletta | 85,000 | 85,000 |
Material Changes
- Compensation Structure: Base salaries for all named executive officers were increased effective June 5, 2017.
- Equity Incentives: New stock option grants totaling 540,000 shares were awarded to executive officers.
- Bonus Plan: A new 2017 Bonus Plan was approved, linking compensation to clinical development, operational, strategic, and financial goals.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or market outlook. Corporate goals for the bonus plan include clinical development, operational, strategic, and financial targets, though specific metrics are not detailed in this report. The full text of the 2017 Bonus Plan is referenced as an exhibit to the upcoming Form 10-Q for the quarter ending June 30, 2017.
Change in Control Provisions: Options for Mr. Duvall, Dr. Gruber, and Mr. Foletta provide for full acceleration upon a change in control. Dr. Das's options provide for acceleration of up to 25% in such an event. All options provide for up to 25% acceleration in the event of death or disability.
Investor Verification Checklist
- Verify the total dilution impact of the 540,000 new stock options granted.
- Review the upcoming Form 10-Q (due for the period ending June 30, 2017) for the full text of the 2017 Bonus Plan and specific performance metrics.
- Confirm the company's cash position to ensure it can sustain the increased fixed salary costs and potential bonus payouts.
- Monitor the vesting schedule and potential acceleration triggers related to change in control events.